Josef M. Miller

OtoMedicine, Inc. is a new biopharmaceutical company, founded in 2006, to commercialize more than two decades of scientific research and technology developed in the laboratories of Dr. Josef Miller at the University of Michigan's Kresge Hearing Research Institute. OtoMedicine's mission is to become the leading provider of medicines to prevent, treat, and cure hearing loss. Its initial focus is to amplify, in a compelling manner, the evidence it has already gathered to demonstrate that a proprietary combination of compounds can dramatically reduce noise-induced hearing loss (NIHL), one of the most prevalent disabling conditions in the industrialized world and for which there is no FDA-approved means of treatment. Called AuraquellTM, this specific combination of micronutrients has already been shown to provide significant synergistic protection against noise-induced injury in pre-clinical studies with animal subjects. In other words, the protection resulting from administration of the combination was greater than that following any of the ingredients individually. Based on the dramatic protection observed in pre-clinical studies, this formulation is expected to be a highly effective therapy for prevention of NIHL in humans.

OtoMedicine, Inc. is a new biopharmaceutical company, founded in 2006, to commercialize more than two decades of scientific research and technology developed in the laboratories of Dr. Josef Miller at the University of Michigan's Kresge Hearing Research Institute. OtoMedicine's mission is to become the leading provider of medicines to prevent, treat, and cure hearing loss. Its initial focus is to amplify, in a compelling manner, the evidence it has already gathered to demonstrate that a proprietary combination of compounds can dramatically reduce noise-induced hearing loss (NIHL), one of the most prevalent disabling conditions in the industrialized world and for which there is no FDA-approved means of treatment. Called AuraquellTM, this specific combination of micronutrients has already been shown to provide significant synergistic protection against noise-induced injury in pre-clinical studies with animal subjects. In other words, the protection resulting from administration of the combination was greater than that following any of the ingredients individually. Based on the dramatic protection observed in pre-clinical studies, this formulation is expected to be a highly effective therapy for prevention of NIHL in humans.